A pacemaker that is no bigger than a vitamin and more comfortable than ever for users: this is now possible at the CIUSSS of Estrie-CHUS. And successfully!
In fact, the statistics speak for themselves: the new MICRA stimulator is 93% smaller than a conventional pacemaker and is successfully implanted in 99% of users.
Dr. Charles Dussault, cardiologist electrophysiologist at the CIUSSS of Estrie-CHUS, recently implanted this new type of pacemaker in the heart of a user with his team at Hôpital Fleurimont.
The innovative MICRA technology will now be used at the CIUSSS of Estrie-CHUS for those who can not use a regular pacemaker.
Recently approved by Health Canada, the MICRA pacemaker will be used in Estrie as an alternative to traditional pacemakers for certain users in particular, especially patients with no access to vascular or requiring hemodialysis or users for whom traditional pacemakers with probes prevent the heart valves from doing their job well.
The MICRA pacemaker can be placed directly into the heart using a catheter without a heart probe. It does not require a large surgery, such as when installing a regular device, since it is inserted into the femoral vein.
It is therefore a minimally invasive procedure. In addition, the device does not require a surgical “pocket” to be created under the skin. The device is not visible and is more comfortable for the user. The stimulator also allows complete MRIs, offering professionals the ability to perform imaging exams.
It was a user from Moncton who allowed Dr. Dussault to install the first MICRA stimulator. Carrying a traditional cardiostimulator that prevented its tricuspid valve from functioning properly, the implant of a MICRA stimulator allowed to extract its old device to allow its valve to operate normally. A partnership with the Dr. Georges-L.-Dumont University Hospital Center made the intervention possible.
“This is an extraordinary technological breakthrough. MICRA is successfully implanted in almost 99% of users. The risk of major complications is very low. We look forward to being able to offer it to more users, “says Dr. Dussault.